XML 121 R66.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Balance Sheet Components - Additional Information (Detail)
$ in Thousands
12 Months Ended
Dec. 31, 2019
USD ($)
Milestone
Dec. 31, 2018
USD ($)
Dec. 31, 2017
USD ($)
Jan. 01, 2019
USD ($)
Schedule of Available-for-sale Securities [Line Items]        
Number of regulatory milestones | Milestone 2      
Unbilled contract assets $ 180,000 $ 0    
Building shell cost 143,107 192,397    
Accumulated depreciation 100,364 65,199    
Depreciation expense 11,147 6,562 $ 6,099  
API product price change in estimated variable consideration 36,324 0    
Accrued long-term co-promotional expenses 53,071 0    
Building shell [Member]        
Schedule of Available-for-sale Securities [Line Items]        
Building shell cost 0 53,880    
Building [Member] | Build to suit arrangements [Member]        
Schedule of Available-for-sale Securities [Line Items]        
Accumulated depreciation   13,500    
Leasehold improvements [Member]        
Schedule of Available-for-sale Securities [Line Items]        
Building shell cost 101,548 $ 101,200    
Leasehold improvements [Member] | Accounting standards update 2016-02 [Member]        
Schedule of Available-for-sale Securities [Line Items]        
Accumulated depreciation       $ 38,900
Europe [Member]        
Schedule of Available-for-sale Securities [Line Items]        
Unbilled contract assets 130,000      
Astellas Agreement [Member] | Europe [Member]        
Schedule of Available-for-sale Securities [Line Items]        
Unbilled contract assets 130,000      
AstraZeneca Agreements [Member]        
Schedule of Available-for-sale Securities [Line Items]        
Unbilled contract assets 50,000      
Accrued long-term co-promotional expenses 53,100      
AstraZeneca Agreements [Member] | U.S./RoW [Member]        
Schedule of Available-for-sale Securities [Line Items]        
Unbilled contract assets $ 50,000